Neurology® Podcast

1) Clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Angela Vincent about her paper on the clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits. Dr. James Addington is reading our e-Pearl of the week about navigating painful neuropathies. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Steve Zeiler about the topic of stroke in the setting of CNS vasculitis. The participants had nothing to disclose except Drs. Vincent, Addington, Johansen and Zeiler.Dr. Vincent serves on the advisory editorial board Journal of Neurology; holds patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG; was a consultant with Athena Diagnostics; occasional small honoraria, travel and speaker honoraria from Baxter International Inc. and Biogen Idec; receives royalties from Athena Diagnostics (MuSK assays), from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010); and receives research support from the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Zeiler receives research support from Johns Hopkins Neurology and NIH; has provided expert legal testimony in 2013 and 2014.

1) Age of first exposure to football and the effect of later-life cognitive impairment on former NFL players and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Robert Stern about his paper on the age of first exposure to football and the effect of later-life cognitive impairment on former NFL players. Dr. James Addington is reading our e-Pearl of the week about REM behavior disorder. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Endocrine disorders. The participants had nothing to disclose except Drs. Goodkin, Stern, Addington, Johansen and Barrett.Dr. Goodkin serves on the scientific advisory board for Tuberous Sclerosis Alliance and CURE Infantile Spasms; serves as an editorial board member of Neurology, Surgical Neurology International and Epilepsia; receive a royalty from UpToDate for co-authorship of an entry entitled The "choking game" and other strangulation activities in children and adolescents; will be receiving royalties for editing Epilepsy as part of the Neurology in Practice series and receives research support from the NIH.Dr. Stern serves as an Associate Editor of Journal of Neuropsychiatry and Clinical Neurosciences; serves as an editorial board member of Archives of Clinical Neuropsychology; serves as a Review Editor of Frontiers in Neurotrauma and Frontiers in Sports Neurology; serves as Series Editor of Alzheimer's Research and Therapy; serves on the Mackey-White Traumatic Brain Injury Committee of the National Football League Players Association; serves on the medical advisory board of Sports Legacy Institute, the National Graves' Disease Foundation and Amarantus Biosciences (paid advisor); serves on the Medical and Scientific Advisory Committee of the MA/NH Chapter of the Alzheimer's Association; is a consultant for Janssen Research & Development and Athena Diagnostics; receives publishing royalties from Psychological Assessment Resources, Inc. for the Visual Analog Mood Scales, the Boston Qualitative Scoring System for the Rey-Osterreith Complex Figure, and the Neuropsychological Assessment Battery; receives research support from Eisai Inc., Eli Lilly and Company, Amarantus Biosciences, Aethlon Medical, Avid Radiopharmaceuticals, the Department of Defense and the NIH; received honorariums from, Braintree Neurorehabilitation Conference, National Academy of Neuropsychology, Harvard Medical School, The German Center for Research and Innovation and Ludwig-Maximilians-Universitat Munchen, Medical University of South Carolina, Spaulding Rehabilitation Hospital and 8th Annual National Summit on Sports Concussion.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

1) PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Jeffrey Vance about his paper on the PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about a mnemonic for the clinical manifestations of CADASIL. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Renal disease. The participants had nothing to disclose except Drs. Vance, Addington, Johansen and Barrett.Dr. Vance serves as an editorial board member of American Journal of Neurodegenerative Diseases; speaker honoraria from Movement Disorders Society, Society of Neuroscience, Hussman Foundation, travel reimbursement for NIH for meeting on Parkinson Disease and NIH for study section; has patents for method of detecting Charcot-Marie-Tooth disease type 2A, TRPC6 involved in glomerulonephritis and methods for identifying an individual at increased risk of developing coronary artery disease; receives research support from NIH; receives royalties for invention from Duke University.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

1) Utilization of antiepileptic drugs in pregnant women in Florida Medicaid and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Xuerong Wen about her paper on the utilization of antiepileptic drugs in pregnant women in Florida Medicaid. Dr. James Addington is reading our e-Pearl of the week about primary orthostatic tremor. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Victor Urrutia about the topic of hemoglobinopathies and stroke. The participants had nothing to disclose except Drs. Fountain, Addington, Johansen and Urrutia.Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Urrutia serves as a Guest Editor for Frontiers; was asked to consult for New York University to conduct a stroke center certification mock survey; receives research support from Genentech, Inc. and the NIH.

Therapeutics in Epilepsy. Lesson of the Week interviews from April 2014.

1) Aspirin and intracerebral hemorrhage: Where are we now and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Reza Behrouz about his paper on where we are regarding aspirin use in relation to intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about POLG mutations in neurologic disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about some of his recent discoveries regarding pathogenic mechanism in autoimmune encephalitis, as well as current challenges facing autoimmune neurology. The participants had nothing to disclose except Drs. Southerland, Behrouz, Numis and Dalmau.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Behrouz serves as a Contributing Editor to Practical Neurology and as an Associate Editor for BioMed Central Neurology; and has participated in medico-legal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau.Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Optimal achieved blood pressure in acute intracerebral hemorrhage and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Craig Anderson about his paper on the optimal achieved blood pressure in acute intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about neuropathy in Fabry disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of autoimmune and paraneoplastic encephalitis and how recent discoveries have changed our understanding of these disorders. The participants had nothing to disclose except Drs. Anderson, Numis and Dalmau.Dr. Anderson serves as an editorial board member of Stroke, Cerebrovascular Diseases, and Medical Journal of Australia; receives honoraria from serving on the scientific advisory board for Pfizer Inc and The Medicines Company; receives funding for travel from Takeda China and Covidien; and receives research support from the National Health and Medical Research Council (NHMRC) of Australia.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

Movement Disorder Emergencies. Lesson of the Week interviews from November 2014.